decisionhealth Newsletters, Part B News - 2007 Issue 4 (April)
Sample these new modifiers for how ESRD patients get drugs
Subscribe or sign in to view the full article.
Article Overview
This article explains a CMS update about new reporting modifiers for end-stage renal disease drug claims and places the change in the context of Medicare billing guidance. It is aimed at coders, billers, and reimbursement staff who handle ESRD-related drug claims and need to understand the scope of the update and the affected code set.
Why This Topic Matters
The article matters because it highlights a Medicare reporting change that affects how ESRD drug claims are identified. Understanding the update helps billing teams stay aligned with CMS guidance as the modifiers move toward required use.
What You Will Learn
- The CMS context for new ESRD drug-reporting modifiers
- Which broad claim-reporting changes the article discusses
- What type of Medicare guidance the update appears in
- The ESRD drug codes referenced in the article
- The modifiers referenced for this reporting change
Who Should Read This
- Medical coders
- Medical billers
- Revenue cycle staff
- Compliance staff
- Dialysis billing personnel
Codes Discussed
Modifiers Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com